A detailed history of Pnc Financial Services Group, Inc. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 73 shares of BCAB stock, worth $38. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73
Previous 73 -0.0%
Holding current value
$38
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$1.37 - $3.92 $685 - $1,960
-500 Reduced 87.26%
73 $0
Q1 2024

May 10, 2024

BUY
$1.88 - $3.46 $940 - $1,730
500 Added 684.93%
573 $1,000
Q4 2023

Feb 09, 2024

BUY
$1.27 - $3.18 $92 - $232
73 New
73 $0

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $19.2M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.